IP Library Granted Patent US 11,951,177
Granted Patent B2
US 11,951,177 · App. 18/187,904 · Granted Apr 9, 2024

High sterol-containing lipid nanoparticles

Inventors: Kevin An (Vancouver, CA); Daniel Kurek (Vancouver, CA); Jayesh Kulkarni (Vancouver, CA); Dominik Witzigmann (Vancouver, CA)
Assignee: NanoVation Therapeutics Inc.
A61K47/6909A61K31/575A61K31/661C12N15/113
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,951,177
App. No.
18/187,904
Granted
Apr 9, 2024
Kind
B2
Abstract

The present disclosure provides a lipid nanoparticle comprising: a nucleic acid cargo molecule; sterol or a derivative thereof present at elevated content; neutral lipid; an ionizable lipid; and a hydrophilic polymer-lipid conjugate present at a content between 0.5 and 3 mol %, wherein each mol % content is relative to total lipid present in the lipid nanoparticle.

Claims (22)

1. A lipid nanoparticle comprising:

a nucleic acid cargo molecule;

a sterol or a derivative thereof present at a mol % content between 49 mol % and 85 mol %;

a phospholipid content of 4 mol % or less;

an ionizable lipid content that is less than 40 mol %; and

a hydrophilic polymer-lipid conjugate present at a content between 0.5 and 2.5 mol %,

wherein each mol % content is relative to total lipid present in the lipid nanoparticle.

2. The lipid nanoparticle of claim 1 , wherein the sterol or the derivative thereof is present at a content of at least 50 mol %.

3. The lipid nanoparticle of claim 1 , wherein the sterol or the derivative thereof is present at a content of at least 52 mol %.

4. The lipid nanoparticle of claim 1 , wherein the ionizable lipid is present at a content that is less than 38.5 mol %.

5. The lipid nanoparticle of claim 1 , wherein the ionizable lipid is present at a content that is less than 35.5 mol %.

6. The lipid nanoparticle of claim 1 , wherein the ionizable lipid is present at a content that is less than 34.5 mol %.

7. The lipid nanoparticle of claim 1 , wherein the ionizable lipid is present at a content that is less than 33.5 mol %.

8. The lipid nanoparticle of claim 1 , wherein the ionizable lipid is present at a content that is less than 32.5 mol %.

9. The lipid nanoparticle of claim 1 , wherein the cargo molecule is siRNA, mRNA, vector nucleic acid, an antisense oligonucleotide or is a nucleic acid-protein or peptide complex.

10. The lipid nanoparticle of claim 1 , wherein the cargo molecule is siRNA, vector nucleic acid or an antisense oligonucleotide.

11. The lipid nanoparticle of claim 1 , wherein the ionizable lipid is an amino lipid.

12. The lipid nanoparticle of claim 1 , wherein the sterol derivative is a non-cationic lipid.

13. The lipid nanoparticle of claim 1 , wherein the sterol is cholesterol or the sterol derivative is a cholesterol derivative.

14. The lipid nanoparticle of claim 1 , wherein the phospholipid is present at 0.5 to 3 mol %.

15. The lipid nanoparticle of claim 14 , wherein the phospholipid is a phospholipid- cholesterol conjugate.

16. The lipid nanoparticle of claim 15 , wherein the phospholipid-cholesterol conjugate is a phosphatidylcholine-cholesterol conjugate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2023
From: AN, KEVIN; KUREK, DANIEL; KULKARNI, JAYESH; WITZIGMANN, DOMINIK
To: NANOVATION THERAPEUTICS INC.
Reel/Frame 063243/0786 →
Continuity (2)
Provisional Application 63269815 · Mar 23, 2022
Related Publication 20230302153A1 · Sep 28, 2023
Cited By (2)
US 12,559,450 US 12,605,464